# Joint Nordic Procurement of Pharmaceuticals 2027 NF2.701.b

- **Source:** TED · `171810-2026`
- **Buyer:** Amgros I/S
- **Published:** 2026-03-12
- **Deadline:** 2026-05-12
- **Estimated value:** 9,036,848 EUR
- **CPV codes:** 33600000
- **Place-of-performance NUTS:** DK011, DNK
- **Buyer-address NUTS:** —
- **Notice type:** cn-standard / 16

## Procedure details

Source lists may span several lots; list positions do not establish relationships.

### Procedure Types

- open

### Award Criterion Descriptions

- Pris, Please refer to section 10 in the tender specifications.
- Stability, Please refer to section 10 in the tender specifications.
- Additional proctetive material, Please refer to section 10 in the tender specifications.
- Environment, Please refer to section 10 in the tender specifications.
- Security of supply, Please refer to section 10 in the tender specifications.

### Selection Criterion Descriptions

- Financial Relations: This Tender is a public procurement, and there are no minimum suitability requirements. Therefore, the criteria 'financial relationship' are not applied. However, for systeme technical reasons a note regarding this procurement has been included in the description section/collumn.

### Options

- Clause 8.2 of the framework agreement provides for an option for delivery in a preagreement period (i.e. before the purchase period begins) and an option for delivery in a postagreement period (i.e. after the purchase period). The two options may be exercised on the terms and conditions stipulated in the framework agreement. The estimated duration in section 5.1.3 is including the options for renewals. The framework agreements ordinary duration is from 1.10.2027 - 30.9.2029.

### Question Deadlines

- 2026-05-01+02:00

### Documents Urls

- https://levportal.amgros.dk/Sider/Default.aspx

### Submission Urls

- https://levportal.amgros.dk/Sider/Default.aspx

## Description

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. A framework agreement will cover delivery of the pharmaceuticals in all three countries. However, for the lot numbers 1-3 the supplier shall only deliver the pharmaceuticals to Denmark and Norway. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.

## Original notice

https://ted.europa.eu/da/notice/-/detail/171810-2026